07-22-2010... NOVELOS THERAPEUTICS ANNOUNCES $1.5 MILLION REGISTERED DIRECT OFFERING...
See News section for details...

07-12-2010... NOVELOS THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 RESULTS IN NOV-002 NEOADJUVANT BREAST CANCER TRIAL AT SYLVESTER COMPREHENSIVE CANCER CENTER, AT THE UNIVERSITY OF MIAMI...
See News section for details...

 

About Us
Click Here for Corporate Slide Presentation
Click Here for Corporate Overview

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. Novelos is seeking to build a pipeline through licensing or acquiring clinical stage compounds or technologies for oncology indications. Our lead compound, NOV-002, has been administered to approximately 1,000 cancer patients in clinical trials and is in Phase 2 development for solid tumors in combination with chemotherapy. Novelos has a partnership with Mundipharma, an independent associated company of Purdue Pharma, to develop and commercialize NOV-002 in Europe and Asia (excluding China). Novelos' second compound, NOV-205, which has been administered to approximately 200 hepatitis patients in clinical trials, is in Phase 2 development for chronic hepatitis C non-responders.

Product Pipeline


We own all intellectual property rights worldwide (excluding the Russian Territory) related to both of our clinical-stage compounds, i.e., NOV-002 and NOV-205, and other pre-clinical compounds based on oxidized glutathione. We have six issued patents in the U.S. We also have two issued patents in Europe and one in Japan. Overall, we have filed more than 30 patent applications worldwide.

Top